SpliceBio is a genetic medicines company that develops gene therapies using its proprietary Protein Splicing platform. The technology is based on research conducted in the Muir Lab at Princeton University over more than 20 years of intein and protein engineering research.

SpliceBio

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

June 13th marks Rare Chromosome & Gene Disorder Awareness Day, a day which aims to raise awareness and encourage a greater understanding of rare chromosome and gene disorders amongst all.
 
Join us in raising awareness about the daily challenges faced by those affected, and their families, by unique genetic variations.
 
At #SpliceBio, we are focused on developing life-changing #genetherapies using our proprietary #ProteinSplicing platform which offers the potential to address diseases that currently cannot be treated with gene therapies, due to the necessary gene being too large to be delivered by adeno-associated virus (AAV) vectors.
 
Our lead program, SB007 targets #Stargardtdisease, a genetic eye disease that causes vision loss in children and adults. Stargardt disease is the most common inherited retinal disorder, affecting 1 in 8,000 to 10,000 people.
 
#biotech #retinaldiseases #lifesciences #genetherapy #rarechromoday #shinebrighttogether

Meet the #SpliceBio team at the Jefferies Healthcare Conference this week!
 
Our CBO, Gerard Caelles, will be in New York from 4-6 June for the event.
 
#Jefferies is one of the world’s leading full-service investment banking and capital markets firms and we look forward to networking with fellow attendees!
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

To mark the month of May being #HealthyVisionMonth, we dedicate our full support and join this years' focus on shining a light on vision loss and its effect on mental health.
 
This year we encourage people to spread the word and reframe your future by helping yourself and others to live their best lives with vision loss.
 
At #SpliceBio we are developing a gene therapy program for #Stargardtdisease, a rare genetic eye disease that causes vision loss in children and adults. Stargardt disease is the most common inherited retinal disorder caused by mutations in a single gene, ABCA4 and affects 1 in 8,000 to 10,000 people.
 
With no approved therapy and a great unmet medical need, we aim to create life-changing therapies at #SpliceBio for patients affected by Stargardt disease.
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

The #SpliceBio team have had a great few days in San Sebastián for #BioEquityEurope 2024 where our CEO, Miquel Vila-Perello, gave a presentation on SpliceBio's #proteinsplicing platform and lead #genetherapy program in Stargardt disease. 
 
Get in touch with us to find out more about our pipeline and latest developments!
 
#biotech #retinaldiseases #lifesciences

Great to see our CEO, Miquel Vila-Perello, featured in pharmaphorum's recent article on the upbeat mood amongst the #lifescience community as the conference season begins in London. 
 
Click the article linked below to read Miquel's thoughts on the #genetherapy landscape following the Anglonordic Life Science Conference.
 
https://lnkd.in/eUEjiUsj
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

💡Our founder and CEO Miquel Vila-Perello was invited today at the #BioEquityEurope panel "Scaling Up Europe's Academic Engine in Cell and Gene Therapy" to share his insights and experience on building and growing a gene therapy startup in Europe in Barcelona 🚀📈  

Thank you to the Session Chair Karen Tkach Tuzman and the rest of the panelists for a fantastic discussion in the wonderful city of San Sebastián! Jean-Philippe Combal Jimmy V. Elisa Petris Mark Kotter Dmitry 'Dima' Kuzmin

The SpliceBio team is wrapping up this week in Baltimore, MD for the Annual Meeting of the American Society of Gene & Cell Therapy #ASGCT2024, where we presented our work on SB007, a novel gene therapy that harnesses the power of engineered split inteins to address Stargardt disease.

From right to left: Miquel Vila-Perello, co-founder and CEO; Marianna Di Scala, Director and Head of Translation, and Gerard Caelles, Chief Business Officer.

If you are attending #BioEquityEurope2024, come and meet our CEO, Miquel Vila-Perello and CBO, Gerard Caelles, next week in San Sebastian! 
 
Join Miquel on 13 May, where he will participate on a panel, titled ‘Scaling Up Europe’s Academic Engine in Cell and Gene Therapy' where he will provide his thoughts on the current cell and gene therapy landscape at 11:15 CEST.
 
At 15:45 CEST on 13 May, Miquel will present 🎤 on SpliceBio's proprietary Protein Splicing platform and lead #GeneTherapy program, SB007, where he will provide an update on the Company's latest developments.
 
Schedule a 1-1 meeting with the team at BioEquity via the online partnering portal here https://bit.ly/3JJQ0r1 or reach out directly via LinkedIn.
 
Revolutionizing genetic medicine with its proprietary Protein Splicing platform!
 
#biotech #retinaldiseases #lifesciences #ProteinSplicing #genetherapy

Save the date🗓️! We are presenting 📢 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 in Seattle, US! 
 
Join our R&D and clinical team at SpliceBio on 9 May at 08:00-09:45 PDT, where we will be presenting a poster on SB007, our novel gene therapy targeting Stargardt disease, an inherited retinal disorder that leads to blindness in patients. David Favre Julian Esteve-Rudd Aniz Girach John Tobin Jonathan Vine
 
ARVO brings together eye and vision scientists from across the globe to Seattle, Washington to showcase new #research and network with experts in the field.
 
Reach out if you would like to meet with the team at #ARVO via info@splice.bio or direct via LinkedIn.
 
#ARVO2024 #retinaldiseases #lifesciences #ProteinSplicing #genetherapy #ophthalmology

We are pleased to announce that our CMO, Aniz Girach, is presenting at the Retinal Cell and Gene Therapy Innovation Summit today! 
 
If you are attending the event, make sure to see Aniz's presentation, titled 'Intein-based dual-AAV gene therapy for Stargardt disease', from 09:50 – 10:05 PDT.
 
Get in touch to arrange a meeting with the team and find out more about SpliceBio's lead #genetherapy program targeting #Stargardtdisease.
 
#biotech #retinaldiseases #lifesciences

news impact assignment basic	general
public peers	general	Aug 25, 2024 2:41 PM	75eb7872
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 25, 2024 2:41 PM	7f4bf5b3
translate crunchbase fundingrounds	general
peers	general	Aug 25, 2024 2:41 PM	72afc58d
news basic	general	Aug 25, 2024 2:41 PM	525cd03b
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

SPLI

BIO:SPLICE

SpliceBio